AstraZeneca picks outspoken (and sometimes critical) prof to join board

Just who is the neuroscientist and university professor AstraZeneca ($AZN) has nominated to its board of directors? A sometime critic of the pharma industry, the Financial Times points out. Dr. Cornelia (Cori) Bargmann has tweeted about GlaxoSmithKline's ($GSK) "obfuscation" over a drug's side effects and called Ranbaxy Laboratories, the Indian drugmaker that has struggled with quality problems, "appalling," the FT notes. Report (reg. req.)